Form 4: Eledon Director Jan Hillson Acquires Shares via RSU Vesting

Eledon Pharmaceuticals Director Jan Hillson acquired 3,430 shares of common stock through the settlement of vested restricted stock units.

Summary

• Jan Hillson, a Director of Eledon Pharmaceuticals, Inc. (ELDN), acquired 3,430 shares of common stock.
• The acquisition occurred on January 10, 2026, through the settlement of restricted stock units (RSUs).
• The RSUs were initially issued on January 10, 2025, and vested 100% on January 10, 2026.
• The transaction price for the common stock acquired was $0, as it represents the conversion of vested RSUs.
• Following this transaction, Jan Hillson directly beneficially owns 3,430 shares of Eledon Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where a director acquired shares through the vesting of restricted stock units. This is generally viewed as a neutral to slightly positive event as it increases insider ownership, aligning interests with shareholders, but does not reflect new operational or financial performance.

Positives

• Increased direct ownership by a company director, which can signal confidence in the company's future prospects.
• The transaction is a result of a pre-existing equity compensation plan (RSUs vesting), aligning management incentives with shareholder interests.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This insider transaction is a routine event related to executive compensation and does not provide specific insights into broader industry trends or competitive positioning.

Related Party Transactions

• Acquisition of 3,430 shares of common stock by Director Jan Hillson through the settlement of restricted stock units.

Stakeholder Impact

• Shareholders: May view the increased direct ownership by a director as a positive signal of confidence in the company's future prospects.

Key Dates

Keywords

Eledon Pharmaceuticals, ELDN, Jan Hillson, Form 4, Insider Trading, Restricted Stock Units, RSU, Common Stock, Director, Share Acquisition